Cellectis

Cellectis was founded by André Choulika in 1999.{{cite web|url=http://labiotech.eu/how-servier-saved-cellectis-the-french-car-t-miracle/ |title=How Servier saved Cellectis, the French CAR-T Miracle |publisher=Labiotech.eu |date=15 July 2015 |access-date=16 March 2016|author = Philip Hemme}} It built up a successful business based on the use of Meganuclease in genome engineering. Cellectis became a publicly traded company in 2007, and raised €21.2 million in a stock offering on Euronext. In 2010, it acquired Cyto Pulse, which had developed a new electroporation technology,{{cite web|url=http://www.genengnews.com/gen-news-highlights/cellectis-acquires-electroporation-firm-cyto-pulse-for-2-2m-in-cash/81243898/f |title=Genetic Engineering & Biotechnology News - Biotech from Bench to Business |publisher=Genengnews.com |date=8 November 2013 |access-date=16 March 2016 |url-status=dead |archive-url=https://web.archive.org/web/20160322171538/http://www.genengnews.com/gen-news-highlights/cellectis-acquires-electroporation-firm-cyto-pulse-for-2-2m-in-cash/81243898/f |archive-date=22 March 2016 }} and in 2011 it paid €28 million for Cellartis, a Swedish biotechnology company.{{r|labio}} In January 2011 the company licensed TALEN gene-editing technology from Iowa State University and the University of Minnesota.{{cite journal|last1=Marx|first1=V|title=Genome-editing tools storm ahead.|journal=Nature Methods|date=November 2012|volume=9|issue=11|pages=1055–9|doi=10.1038/nmeth.2220|pmid=23132115|s2cid=20875262|doi-access=free}}{{Cite web|url=https://www.genengnews.com/gen-news-highlights/cellectis-nabs-tal-effector-ip-from-minnesota-and-iowa-state/81244555/|title=Cellectis Nabs TAL Effector IP from Minnesota and Iowa State Universities|website=GEN|date=January 20, 2011}} The company employed nearly 300 people in early 2014.{{r|labio}}

With the advent of the CRISPR (clustered regularly interspaced short palindromic repeat) genome editing technique, the Cellectis meganuclease technology became uneconomic, and by 2013 the company was close to bankruptcy. It restructured, closed laboratories and reduced staff, and shifted research emphasis toward CAR-T technologies for cancer immunotherapy. Early in 2014 it reached a substantial financing deal with Servier, and later in the same year made a much larger agreement with Pfizer and Allogene.{{r|labio}}

In March 2015 the company raised $228 million through a stock offering on NASDAQ. The shares fell by 15% in the first week of trading.{{Cite news|url=http://www.nasdaq.com/article/us-ipo-weekly-recap-solaredge-shines-while-other-ipos-fall-flat-cm459895|title=US IPO Weekly Recap: SolarEdge shines while other IPOs fall flat|date=27 March 2015|work=NASDAQ.com|access-date=18 September 2017|language=en-us}}

Cellectis has two manufacturing facilities - one in Paris, France, and one in Raleigh, North Carolina.{{Cite web |title=Cellectis to bring CAR-T manufacturing in-house with new plants |url=https://www.biopharmadive.com/news/cellectis-to-bring-car-t-manufacturing-in-house-with-new-plants/550104/ |access-date=2019-07-11 |website=BioPharma Dive |language=en-US}}

Cellectis formed the subsidiary of Calyxt in 2010{{Cite web|url=https://www.bizjournals.com/twincities/news/2017/07/21/biotech-firm-calyxt-goes-public-shares-climb-30.html|title=Biotech firm Calyxt goes public, shares climb 30 percent|last=Rehkamp|first=Patrick|date=21 July 2017|website=www.bizjournals.com|access-date=2017-10-08}} to develop healthier food ingredients through gene editing.{{Cite news|url=https://www.wired.com/story/the-first-gene-edited-food-is-now-being-served/|title=The First Gene-Edited Food Is Now Being Served|work=Twin Cities Business|access-date=2018-01-18}} Based in Roseville, Minnesota, the subsidiary filed for an IPO in June, 2017.{{Cite news|url=http://www.startribune.com/agricultural-biotechnology-company-calyxt-files-for-ipo/431164723/|title=Agricultural biotechnology company Calyxt files for IPO|work=Star Tribune|access-date=2017-10-26}}

Cellectis has developed CAR T-cell treatments for blood cancer.{{Cite news|url=https://www.scientificamerican.com/article/powerful-childhood-cancer-treatment-holds-promise-and-poses-hazards/|title=Powerful Childhood Cancer Treatment Holds Promise--and Poses Hazards|last=Weintraub|first=Karen|work=Scientific American|access-date=2017-10-08|language=en}} Most CAR-T therapies under development as of 2017 involved taking T-cells from the person with cancer and applying gene therapy to those cells to activate them to attack the person's cancer; an autologous cell therapy approach. Cellectis' approach starts with T-cells taken from healthy donors (allogeneic or allograft) and modifying these base cells with gene editing to disable the gene that causes donor immune cells to attack their host (preventing graft vs host disease). The base cells can then be modified the same way other CAR-T therapeutics are.{{Cite news|url=https://www.newscientist.com/article/2119252-gene-editing-has-saved-the-lives-of-two-children-with-leukaemia/|title=Gene editing has saved the lives of two children with leukaemia|work=New Scientist|access-date=2017-10-08|language=en-US}}

In 2017, UCART123 was in phase 1 trials for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukaemia (AML). In early September 2017, the FDA suspended Cellectis’ Phase I trials of UCART123 in the wake of the death of a BPDCN patient from cytokine release syndrome (CRS).{{Cite web |url=http://www.pharmatimes.com/news/fda_holds_trials_of_cellectis_cell_therapy_after_patient_death_1204313 |title=FDA holds trials of Cellectis' cell therapy after patient death|last=McKee|first=Selina|date=2017-09-05|website=www.pharmatimes.com|language=en|access-date=2017-10-08}} The FDA hold was lifted in November 2017 after reducing the dosage and with additional conditions.[https://immuno-oncologynews.com/2017/11/09/cellectis-receives-fda-approval-resume-ucart123-aml-bpdcn-trials/ FDA Lifts Clinical Hold on Cellectis’ UCART123 Phase 1 Trials in AML, BPDCN. nov 2017] Cellectis also has a phase 1 trial for UCART22 in B-cell acute lymphoblastic leukemia (B-ALL) and received an IND approval from the FDA on their UCARTCS1 product candidate in multiple myeloma.{{Cite web|url=https://myelomaresearchnews.com/2019/04/22/cellectis-clinical-trial-ucartcs1-multiple-myeloma/|title=Possible Multiple Myeloma CAR T-cell Therapy to Enter Phase 1 Trial, Cellectis Says|date=2019-04-22|website=Myeloma Research News|language=en-US|access-date=2019-07-11}}

{{reflist}}

Category:Biotechnology companies of France

Category:Companies listed on Euronext Paris

Category:Biotechnology companies established in 1999

Category:French companies established in 1999